Casdin Partners Master Fund, L.P. has demonstrated a pronounced buying bias in its recent insider trading activity, as evidenced by SEC Form 4 filings. Over the past several months, the fund has executed 23 purchases compared to just two sales, with a total buy value of $153,136,941.24 and a total sell value of $45,261,720. The overwhelming majority of these transactions have been concentrated in Laboratory Corporation of America Holdings (LAB), with purchases occurring consistently from August 2025 through December 2025. Notable transactions include a $9,838,405 purchase on November 25, 2025, and a $541,395 acquisition on November 13, 2025, underscoring the fund’s sustained interest in LAB. In contrast, the fund’s selling activity has been limited to BioLife Solutions, Inc. (BLFS), with two sales totaling $33,610,325, including a $21,410,325 transaction on October 15, 2025. This pattern suggests a strategic shift toward LAB, with Casdin Partners significantly increasing its exposure to the company while reducing its stake in BLFS. The fund’s recent trades reflect a clear directional focus, emphasizing accumulation over divestment.
AI-assisted summary